РОЛЬ ГЕНЕТИЧЕСКИХ ОСОБЕННОСТЕЙ ПАЦИЕНТОВ К КОРРЕКЦИИ НАРУШЕНИЙ ЛИПИДНОГО ОБМЕНА
Abstract
To date, the approach has generated the need for direction of individualization of treatment of the disease in each patient. It is known that the genetic characteristics of the patient more than in sofo can identify inadequate pharmacological response. Given that the metabolism of drugs in the human body is genetically determined, the application of modern pharmacogenetic tests for individual dose lipid-lowering drugs is becoming increasingly important for personalized medicine.
References
Демографический ежегодник России. 2013: cтат. сб. – М.: Росстат, 2013. – 543 с.
Дзвониская, В.Н. Влияние индивидуальных особенностей окислительного метаболизма и генетических факторов на эффект гиполипидемической терапии у больных ишемической болезнью сердца: автореф. дис. канд. мед. наук: 14.03.06 / В.Н. Дзвониская. – Курск, 2011. – 22 с.
Оказание помощи при хронических состояниях. Взгляд с позиций системы здравоохранения / под ред. Ellen Nolte, Martin McKee; Всемирная организация здравоохранения, от имени Европейской обсерватории по системам и политики здравоохранения. – [Женева], 2011 – 256 с.
Global atlas on cardiovascular disease prevention and control / WHO. – Geneva, Switzerland, 2011. – 164 p.
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men / P. Pignoli, E. Tremoli, A. Poli [et al.] // Circulation. – 2005. – Vol. 112. – P. 3375-3383.
Views:
27
Downloads:
22
Copyright (c) 2016 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.